Jacqueline C Barrientos MD MS

PubMed

• 2 citations
  Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL.
  Jacob D Soumerai, Jacqueline Barrientos, Inhye Ahn, Catherine Coombs, Douglas Gladstone
  Blood Advances. 2025-03-11
• Chronic lymphocytic leukemia often arises by a multiclonal selection process.
  Davide Bagnara, Andrea N Mazzarello, Niccolò Cardente, Stefano Vergani, Siddha Kasar
  Haematologica. 2025-02-20
• CLL crosstalk with naïve T cells enhances the differentiation of IL-22-producing T cells and CLL -cell survival.
  Gerardo Ferrer, Florencia Palacios, Pui Yan Chiu, Kelly Wong, Alberto Bueno-Costa
  Leukemia. 2025-02-01

Abstracts/Posters

• Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
  Jacqueline C. Barrientos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By BrutonÍs Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrut...
  Jacqueline C Barrientos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
  Jacqueline C. Barrientos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Jacqueline C Barrientos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
  Jacqueline C. Barrientos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
  Jacqueline C. Barrientos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Defined Duration Frontline Chemoimmunotherapy in Chronic Lymphocytic Leukemia: Less Is More 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
• Ibrutinib Treatment Reduces Myeloid Derived Suppressor Cell Numbers and Function in Chronic Lymphocytic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Extended Survival in CLL Patients Who Discontinued Idelalisib Because of Colitis Correlates with Higher Th17 Levels in Blood and Colon Tissue 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Musashi 2 Is Overexpressed in Poor Outcome CLL Patients and Their Proliferative Fraction and Silencing This Gene Induces Apoptosis and Increases Cell Adhesion and Move... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Making Strides in the Treatment of B-Cell Malignancies: Keeping Up With New Data and Practice Recommendations 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Join now to see all